Trial of a new treatment for high-risk cornea transplants
Part of Eyes & vision clinical trials.
This study tests a new approach to help prevent cornea transplant failure in people with high-risk conditions, such as blood vessels growing into the cornea. It aims to see if this treatment can improve transplant success.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- You must be having a high-risk cornea transplant, which means you have abnormal blood vessels growing into your cornea.
- You cannot have certain eye diseases like Stevens-Johnson syndrome or ocular pemphigoid.
- You cannot have an eye infection or uncontrolled glaucoma.
- You cannot be pregnant or breastfeeding, and if you can get pregnant, you must use reliable birth control.
- You cannot have had eye surgery or a procedure in the last 90 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how well a patient’s corneal lining cells are preserved before corneal transplantation, and uses that to guide the transplant approach. It may help improve transplant planning and outcomes for people who need treatment for conditions like keratoconus or Fuchs endothelial dystrophy.
This trial studies whether pretreatment with a specific vitamin and ultraviolet light can help a future, high-risk corneal transplant keep its new cornea healthy for longer. It may help people whose corneas already have new blood vessels, which can make transplant results harder.
This study tests a lab-grown (ex vivo) method of strengthening donor cornea tissue used in cornea transplants for people with keratoconus. It may help improve how well the transplanted cornea heals and functions.
This study tests a procedure called Xenia corneal lenticule in people with severe keratoconus or severe post-LASIK corneal thinning who want to avoid a corneal transplant. It aims to improve vision while checking safety and how well the new procedure works over time.
This trial studies corneal crosslinking to treat active inflammation or infection that leads to new blood vessels growing into the cornea. It may help reduce ongoing damage and lower the risk of problems, including issues that can threaten a future corneal transplant.
This trial tests a new artificial cornea device (keratoprosthesis) for people with severe corneal scarring or damage who cannot see well and are at high risk for corneal transplant failure. The goal is to restore vision and improve quality of life.
Hear when a new Corneal Transplant Failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.